All In Biotech

Drug Trial Radar · NCT07866105

Study to Determine Efficacy, Safety, and Tolerability of B244 as a Topical Spray in Subjects With Moderate to Severe Acne Vulgaris

A Phase 2b, Randomized, Double-Blind, Vehicle-Controlled Multi-Center Study of the Efficacy, Safety, and Tolerability of B244 Delivered as a Topical Spray in the Treatment of Moderate to Severe Acne Vulgaris

Last checked: Nov 19, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 176 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

176

Planned (sponsor's estimate)

Start

Oct 2026

Primary completion

Aug 2027

Study completion Sep 2027

Sponsor

Lead sponsor
AOBiome LLCIndustry
Sponsor type
Industry
Collaborators
bioRASI, LLC
First posted
Oct 8, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 2b, randomized, double-blind, vehicle-controlled clinical trial evaluating the efficacy, safety, and tolerability of B244 compared to vehicle in the treatment of moderate to severe acne vulgaris in adolescents and adults. Participants who meet the study entry criteria will be randomized in a 1:1 ratio to receive twice daily topical doses of B244 O.D. 5.0 or vehicle (control) for 12 weeks.

Conditions

  • Acne Vulgaris

Interventions

  • B244Biological

    B244 suspension

  • VehicleBiological

    Vehicle suspension

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of participants with IGA success, defined as IGA 0 (clear) or 1 (almost clear) and ≥2-point improvementTime frame: Baseline to Week 12

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.